{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T16:14:06Z","timestamp":1772640846702,"version":"3.50.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Unidade Local de Sa\u00fade de Coimbra"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Breast cancer is a heterogeneous malignant disease that remains as one of the most prevalent cancers globally. Triple negative breast cancer (TNBC) accounts for 15% of the total of breast cancers and presents high tumor immunogenicity and a tumor microenvironment that plays a critical role in disease progression and patient outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study evaluated a total of 30 tissue samples from female patients with TNBC, to characterize specific immune cells within the tumor tissue and investigate their relationship with short (pathological complete response, pCR), long (disease-free survival, DFS) and clinical outcomes. Tumor-infiltrating lymphocytes (TIL) were assessed by immunohistochemistry (IHC) on tissue microarrays (TMA), complemented by digital analysis for standardized quantification.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Our results highlight the influence of CD4\u207a T cells on short-term outcomes: high CD4\u207a T-cell levels were significantly associated with achieving pCR. High CD8\u207a T-cell levels were also significantly associated with axillary lymph node negativity.Regarding long-term outcomes, higher CD4\u207a, CD8\u207a and FOXP3\u207a T-cell levels showed a non-significant tendency toward improved DFS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These findings suggest that high levels of CD4\u2009+\u2009T cells and CD8\u2009+\u2009T cells are positive predictors of immediate, long-term prognosis and clinical prognosis in patients with TNBC. This study enhances the understanding on the immunological interests in specific subtypes of TIL and identifies potential biomarkers that could drive advancements in precision medicine for breast cancer management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12282-025-01819-y","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T11:15:44Z","timestamp":1767784544000},"page":"386-395","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic relevance of specific TIL (CD4+, CD8+, and FOXP3\u2009+\u2009T-cell infiltrates) in triple-negative breast cancer: short- and long-term outcomes"],"prefix":"10.1007","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0825-6732","authenticated-orcid":false,"given":"Olga","family":"Caramelo","sequence":"first","affiliation":[]},{"given":"V\u00e2nia","family":"Almeida","sequence":"additional","affiliation":[]},{"given":"Ana","family":"Fidalgo","sequence":"additional","affiliation":[]},{"given":"Augusta","family":"Cipriano","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7423-2996","authenticated-orcid":false,"given":"Teresa","family":"Almeida-Santos","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2026,1,7]]},"reference":[{"issue":"10","key":"1819_CR1","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1007\/s11912-018-0726-6","volume":"20","author":"A Diana","year":"2018","unstructured":"Diana A, et al. Triple-Negative breast cancers: systematic review of the literature on molecular and clinical features with a focus on treatment with innovative drugs. Curr Oncol Rep. 2018;20(10):76.","journal-title":"Curr Oncol Rep"},{"key":"1819_CR2","doi-asserted-by":"publisher","first-page":"1194020","DOI":"10.3389\/fimmu.2023.1194020","volume":"14","author":"R Li","year":"2023","unstructured":"Li R, Cao L. The role of tumor-infiltrating lymphocytes in triple-negative breast cancer and the research progress of adoptive cell therapy. Front Immunol. 2023;14:1194020.","journal-title":"Front Immunol"},{"issue":"1","key":"1819_CR3","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1111\/tbj.13713","volume":"26","author":"HA Azim","year":"2020","unstructured":"Azim HA, et al. Personalized treatment in metastatic triple-negative breast cancer: the outlook in 2020. Breast J. 2020;26(1):69\u201380.","journal-title":"Breast J"},{"issue":"20","key":"1819_CR4","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1056\/NEJMra1001389","volume":"363","author":"WD Foulkes","year":"2010","unstructured":"Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010;363(20):1938\u201348.","journal-title":"N Engl J Med"},{"issue":"11","key":"1819_CR5","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1007\/s11864-019-0682-x","volume":"20","author":"TG Lyons","year":"2019","unstructured":"Lyons TG. Targeted therapies for Triple-Negative breast cancer. Curr Treat Options Oncol. 2019;20(11):82.","journal-title":"Curr Treat Options Oncol"},{"issue":"1","key":"1819_CR6","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s10549-010-0987-8","volume":"127","author":"SM Mahmoud","year":"2011","unstructured":"Mahmoud SM, et al. An evaluation of the clinical significance of FOXP3\u2009+\u2009infiltrating cells in human breast cancer. Breast Cancer Res Treat. 2011;127(1):99\u2013108.","journal-title":"Breast Cancer Res Treat"},{"issue":"6","key":"1819_CR7","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.3892\/ijo.2020.5135","volume":"57","author":"KA Won","year":"2020","unstructured":"Won KA, Spruck C. Triple\u2013negative breast cancer therapy: current and future perspectives (Review). Int J Oncol. 2020;57(6):1245\u201361.","journal-title":"Int J Oncol"},{"issue":"9","key":"1819_CR8","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1200\/JCO.2014.58.1967","volume":"33","author":"C Denkert","year":"2015","unstructured":"Denkert C, et al. Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. J Clin Oncol. 2015;33(9):983\u201391.","journal-title":"J Clin Oncol"},{"issue":"5","key":"1819_CR9","doi-asserted-by":"publisher","first-page":"355","DOI":"10.4132\/jptm.2015.07.29","volume":"49","author":"SG Ahn","year":"2015","unstructured":"Ahn SG, et al. Current issues and clinical evidence in Tumor-Infiltrating lymphocytes in breast cancer. J Pathol Transl Med. 2015;49(5):355\u201363.","journal-title":"J Pathol Transl Med"},{"key":"1819_CR10","doi-asserted-by":"crossref","unstructured":"Zeng Z et al. Investigating T cell immunity in cancer: achievements and prospects. Int J Mol Sci. 2021;22(6):2907.","DOI":"10.3390\/ijms22062907"},{"issue":"10","key":"1819_CR11","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1001\/jamaoncol.2016.1061","volume":"2","author":"SE Stanton","year":"2016","unstructured":"Stanton SE, Adams S, Disis ML. Variation in the incidence and magnitude of Tumor-Infiltrating lymphocytes in breast cancer subtypes: A systematic review. JAMA Oncol. 2016;2(10):1354\u201360.","journal-title":"JAMA Oncol"},{"issue":"9","key":"1819_CR12","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.tcb.2020.06.003","volume":"30","author":"M St Paul","year":"2020","unstructured":"St Paul M, Ohashi PS. The roles of CD8(+) T cell subsets in antitumor immunity. Trends Cell Biol. 2020;30(9):695\u2013704.","journal-title":"Trends Cell Biol"},{"issue":"4","key":"1819_CR13","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1038\/nrclinonc.2015.215","volume":"13","author":"P Savas","year":"2016","unstructured":"Savas P, et al. Clinical relevance of host immunity in breast cancer: from TILs to the clinic. Nat Rev Clin Oncol. 2016;13(4):228\u201341.","journal-title":"Nat Rev Clin Oncol"},{"issue":"Suppl 1","key":"1819_CR14","doi-asserted-by":"publisher","first-page":"S44","DOI":"10.1016\/S0960-9776(19)31122-1","volume":"48","author":"EF Blackley","year":"2019","unstructured":"Blackley EF, Loi S. Targeting immune pathways in breast cancer: review of the prognostic utility of TILs in early stage triple negative breast cancer (TNBC). Breast. 2019;48(Suppl 1):S44\u20138.","journal-title":"Breast"},{"issue":"7437","key":"1819_CR15","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/nature11824","volume":"494","author":"H Braumuller","year":"2013","unstructured":"Braumuller H, et al. T-helper-1-cell cytokines drive cancer into senescence. Nature. 2013;494(7437):361\u20135.","journal-title":"Nature"},{"key":"1819_CR16","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.molimm.2021.06.013","volume":"137","author":"A Ghods","year":"2021","unstructured":"Ghods A, et al. Regulatory T cells express tumor necrosis factor receptor 2 with the highest intensity among CD4(+) T cells in the draining lymph nodes of breast cancer. Mol Immunol. 2021;137:52\u20136.","journal-title":"Mol Immunol"},{"key":"1819_CR17","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.crimmu.2021.08.002","volume":"2","author":"T Sarkar","year":"2021","unstructured":"Sarkar T, Dhar S, Sa G. Tumor-infiltrating T-regulatory cells adapt to altered metabolism to promote tumor-immune escape. Curr Res Immunol. 2021;2:132\u201341.","journal-title":"Curr Res Immunol"},{"issue":"5","key":"1819_CR18","doi-asserted-by":"publisher","first-page":"387","DOI":"10.5306\/wjco.v7.i5.387","volume":"7","author":"CA Castaneda","year":"2016","unstructured":"Castaneda CA, et al. Tumor infiltrating lymphocytes in triple negative breast cancer receiving neoadjuvant chemotherapy. World J Clin Oncol. 2016;7(5):387\u201394.","journal-title":"World J Clin Oncol"},{"issue":"3","key":"1819_CR19","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1111\/apm.13022","volume":"128","author":"B Cai","year":"2020","unstructured":"Cai B, et al. Composition and plasticity of triple-negative breast carcinoma-infiltrating regulatory T cells. APMIS. 2020;128(3):260\u20139.","journal-title":"APMIS"},{"issue":"1","key":"1819_CR20","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S1470-2045(17)30904-X","volume":"19","author":"C Denkert","year":"2018","unstructured":"Denkert C, et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol. 2018;19(1):40\u201350.","journal-title":"Lancet Oncol"},{"issue":"1\u20132","key":"1819_CR21","first-page":"25","volume":"32","author":"BN Peshkin","year":"2010","unstructured":"Peshkin BN, Alabek ML, Isaacs C. BRCA1\/2 mutations and triple negative breast cancers. Breast Dis. 2010;32(1\u20132):25\u201333.","journal-title":"Breast Dis"},{"key":"1819_CR22","doi-asserted-by":"publisher","first-page":"1095839","DOI":"10.3389\/fgene.2022.1095839","volume":"13","author":"S Loizides","year":"2022","unstructured":"Loizides S, Constantinidou A. Triple negative breast cancer: Immunogenicity, tumor microenvironment, and immunotherapy. Front Genet. 2022;13:1095839.","journal-title":"Front Genet"},{"key":"1819_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0065-2776(06)90001-7","volume":"90","author":"MJ Smyth","year":"2006","unstructured":"Smyth MJ, Dunn GP, Schreiber RD. Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv Immunol. 2006;90:1\u201350.","journal-title":"Adv Immunol"},{"issue":"4","key":"1819_CR24","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1007\/s12282-021-01247-8","volume":"28","author":"J Zhang","year":"2021","unstructured":"Zhang J, et al. Immune-related biomarkers in triple-negative breast cancer. Breast Cancer. 2021;28(4):792\u2013805.","journal-title":"Breast Cancer"},{"issue":"1","key":"1819_CR25","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1186\/s12885-020-07654-y","volume":"20","author":"ZH Gao","year":"2020","unstructured":"Gao ZH, et al. Predictive and prognostic role of tumour-infiltrating lymphocytes in breast cancer patients with different molecular subtypes: a meta-analysis. BMC Cancer. 2020;20(1):1150.","journal-title":"BMC Cancer"},{"issue":"2","key":"1819_CR26","doi-asserted-by":"publisher","first-page":"R48","DOI":"10.1186\/bcr3148","volume":"14","author":"S Liu","year":"2012","unstructured":"Liu S, et al. CD8\u2009+\u2009lymphocyte infiltration is an independent favorable prognostic indicator in basal-like breast cancer. Breast Cancer Res. 2012;14(2):R48.","journal-title":"Breast Cancer Res"},{"key":"1819_CR27","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s40425-016-0165-6","volume":"4","author":"SE Stanton","year":"2016","unstructured":"Stanton SE, Disis ML. Clinical significance of tumor-infiltrating lymphocytes in breast cancer. J Immunother Cancer. 2016;4:59.","journal-title":"J Immunother Cancer"},{"issue":"3","key":"1819_CR28","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1093\/annonc\/mdt556","volume":"25","author":"MV Dieci","year":"2014","unstructured":"Dieci MV, et al. Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study. Ann Oncol. 2014;25(3):611\u20138.","journal-title":"Ann Oncol"},{"issue":"10","key":"1819_CR29","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.1038\/bjc.2013.634","volume":"109","author":"AN Seo","year":"2013","unstructured":"Seo AN, et al. Tumour-infiltrating CD8\u2009+\u2009lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancer. Br J Cancer. 2013;109(10):2705\u201313.","journal-title":"Br J Cancer"},{"key":"1819_CR30","doi-asserted-by":"crossref","unstructured":"Iwase T et al. A Novel Immunomodulatory 27-Gene Signature to Predict Response to Neoadjuvant Immunochemotherapy for Primary Triple-Negative Breast Cancer. Cancers (Basel), 2021. 13(19).","DOI":"10.3390\/cancers13194839"},{"issue":"1","key":"1819_CR31","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s12916-022-02332-1","volume":"20","author":"T Ueno","year":"2022","unstructured":"Ueno T, et al. Immune microenvironment, homologous recombination deficiency, and therapeutic response to neoadjuvant chemotherapy in triple-negative breast cancer: Japan breast cancer research group (JBCRG)22 TR. BMC Med. 2022;20(1):136.","journal-title":"BMC Med"},{"issue":"5","key":"1819_CR32","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1007\/s12282-020-01084-1","volume":"27","author":"T Jamiyan","year":"2020","unstructured":"Jamiyan T, et al. Prognostic impact of a tumor-infiltrating lymphocyte subtype in triple negative cancer of the breast. Breast Cancer. 2020;27(5):880\u201392.","journal-title":"Breast Cancer"},{"key":"1819_CR33","doi-asserted-by":"publisher","first-page":"151676","DOI":"10.1016\/j.anndiagpath.2020.151676","volume":"51","author":"AE Abdelrahman","year":"2021","unstructured":"Abdelrahman AE, et al. Clinicopathological significance of the Immunologic signature (PDL1, FOXP3\u2009+\u2009Tregs, TILs) in early stage triple-negative breast cancer treated with neoadjuvant chemotherapy. Ann Diagn Pathol. 2021;51:151676.","journal-title":"Ann Diagn Pathol"},{"issue":"3","key":"1819_CR34","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s10549-014-3197-y","volume":"148","author":"M Miyashita","year":"2014","unstructured":"Miyashita M, et al. Tumor-infiltrating CD8\u2009+\u2009and FOXP3\u2009+\u2009lymphocytes in triple-negative breast cancer: its correlation with pathological complete response to neoadjuvant chemotherapy. Breast Cancer Res Treat. 2014;148(3):525\u201334.","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"1819_CR35","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s10549-024-07334-6","volume":"207","author":"K Chin","year":"2024","unstructured":"Chin K, et al. Tumor-infiltrating lymphocytes as a predictor of axillary and primary tumor pathological response after neoadjuvant chemotherapy in patients with breast cancer: a retrospective cohort study. Breast Cancer Res Treat. 2024;207(1):49\u201363.","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"1819_CR36","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s12282-023-01442-9","volume":"30","author":"N Tomioka","year":"2023","unstructured":"Tomioka N, et al. Programmed death ligand 1-positive immune cells in primary tumor or metastatic axillary lymph nodes can predict prognosis of triple-negative breast cancer even when present at <\u20091% in the tumor region. Breast Cancer. 2023;30(3):497\u2013505.","journal-title":"Breast Cancer"},{"issue":"4","key":"1819_CR37","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1007\/s12282-020-01049-4","volume":"27","author":"R Goto","year":"2020","unstructured":"Goto R, et al. The number of FoxP3-positive tumor-infiltrating lymphocytes in patients with synchronous bilateral breast cancer. Breast Cancer. 2020;27(4):586\u201393.","journal-title":"Breast Cancer"},{"key":"1819_CR38","doi-asserted-by":"publisher","first-page":"117822342110169","DOI":"10.1177\/11782234211016977","volume":"15","author":"MA Arafah","year":"2021","unstructured":"Arafah MA, et al. KI-67 LI expression in Triple-Negative breast cancer patients and its significance. Breast Cancer (Auckl). 2021;15:11782234211016977.","journal-title":"Breast Cancer (Auckl)"},{"issue":"1","key":"1819_CR39","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s10549-017-4161-4","volume":"163","author":"J Yeong","year":"2017","unstructured":"Yeong J, et al. Higher densities of Foxp3(+) regulatory T cells are associated with better prognosis in triple-negative breast cancer. Breast Cancer Res Treat. 2017;163(1):21\u201335.","journal-title":"Breast Cancer Res Treat"},{"key":"1819_CR40","doi-asserted-by":"crossref","unstructured":"Gupta RK et al. Systemic therapy De-Escalation in Early-Stage Triple-Negative breast cancer: dawn of a new era? Cancers (Basel). 2022;14(8):1856 .","DOI":"10.3390\/cancers14081856"}],"container-title":["Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-025-01819-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12282-025-01819-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-025-01819-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T10:57:33Z","timestamp":1772621853000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12282-025-01819-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,7]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["1819"],"URL":"https:\/\/doi.org\/10.1007\/s12282-025-01819-y","relation":{},"ISSN":["1340-6868","1880-4233"],"issn-type":[{"value":"1340-6868","type":"print"},{"value":"1880-4233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,7]]},"assertion":[{"value":"10 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}